Clinical trials: Nausea With Vomiting Chemotherapy-Induced
Breast Cancer, Drug-induced Nausea and Vomiting
Acupressure in Treating Nausea in Women Receiving Combination Chemotherapy for Breast Cancer
RATIONALE: Acupressure may help to reduce or prevent nausea in patients who are undergoing chemotherapy. It is not yet known whether acupressure plus standard care for nausea is more effective than standard care alone for nausea…
- Trial name
- NCT00046865
- Testing
- acupressure therapy, management of therapy complications, nausea and vomiting therapy
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- M.D. Anderson Cancer Center
Nausea and Vomiting
the Efficacy and Safety of Ondansetron Oral Soluble Pellicles
The name of this prospective study is a multicenter, open-label, randomized controlled clinical study of the efficacy and safety of Ondansetron Oral Soluble Pellicles for the prevention of delayed nausea and vomiting induced by…
- Trial name
- NCT06282211
- Testing
- Ondansetron Oral Soluble Pellicles
- Where
- China
- Volunteers
- 184 people
- Sponsor
- The First Affiliated Hospital of Xinxiang Medical College
Breast Neoplasms
Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer
The goal of this clinical trial is to learn whether Chinese herbal acupoint application, when added to standard three-drug anti-nausea treatment, can prevent nausea and vomiting caused by chemotherapy in people with breast…
- Trial name
- NCT07848984
- Testing
- Chinese Herbal Acupoint Application, Standard Triple Antiemetic Therapy
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Pancreatic Cancer Stage IV, Chemotherapy-induced Nausea and Vomiting
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
The purpose of this study is to evaluate the efficacy of thalidomide on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy.
- Trial name
- PTCA199-5 (NCT06017284)
- Testing
- Thalidomide, Nab paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy
Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study
This is a multicenter, randomized, controlled, double-blind, phase III study.
- Trial name
- OFFER (NCT04536558)
- Testing
- olanzapine plus fosaprepitant-based triple regimen
- Where
- 18 sites in China
- Volunteers
- 352 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Chemotherapy-induced Nausea and Vomiting
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
Chemotherapy is one of the most common treatments for breast cancer, but the adverse effects can be severe enough to delay or make chemotherapy intolerable, thus affecting the efficacy of the disease.
- Trial name
- NCT05841849
- Testing
- Aprepitant, Palonosetron, Fosaprepitant
- Where
- China
- Volunteers
- 1,028 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Chemo-radiation Induced Nausea and Vomiting
Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
The purpose of this phase 2 study is to assess the efficacy and patient satisfaction of oral rolapitant plus ondansetron vs. oral ondansetron monotherapy in malignant glioma (MG) patients receiving standard of care radiation (RT)…
- Trial name
- NCT02991456
- Testing
- Rolapitant, Ondansetron
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Duke University
Chemotherapy-induced Nausea and Vomiting
Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants
The purpose of this research study is to see if olanzapine helps to prevent nausea and/or vomiting (throwing up) when it is added to other medicines in subjects having stem cell transplants.
- Trial name
- NCT04535141
- Testing
- Olanzapine 5 MG
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Chemotherapy-induced Nausea and Vomiting, Nursing Caries
The Effect of Mandala Technique on Acute Nausea-vomiting and Comfort Level in Cancer Patients
Cancer is an important health problem in the world and in our country, and it ranks second among the causes of death in our country (20.7%).
- Trial name
- NCT05885126
- Testing
- MANDALA TECHNIQUE
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Ege University
Neoplasms, Chemotherapy-Induced Nausea and Vomiting
Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting
This purpose of this study is to evaluate the efficacy and safety of single and repeated doses of palonosetron hydrochloride in preventing nausea and vomiting caused by moderate and highly emetogenic chemotherapy in patients.
- Trial name
- ESPNV (NCT01481831)
- Testing
- Palonosetron Hydrochloride
- Where
- 18 sites in China
- Volunteers
- 599 people
- Sponsor
- Shanghai Changzheng Hospital
Chemotherapy-Induced Nausea and Vomiting, Lung Cancer
Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
Aprepitant is an oral neurokinin-1(NK-1) antagonist which is used for the prevention of chemotherapy-induced nausea and vomiting (CINV).
- Trial name
- NCT02445872
- Testing
- Aprepitant, Palonosetron, Dexamethasone
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Zhejiang University
Chemotherapy-induced Nausea and Vomiting
Auricular Acupressure for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Chemotherapy-induced nausea and vomiting (CINV) remains one of the most common and distressing adverse effects in patients receiving highly emetogenic chemotherapy (HEC).
- Trial name
- AACINV (NCT07760766)
- Testing
- Auricular Acupressure
- Where
- China
- Volunteers
- 332 people
- Sponsor
- China Medical University, China
Chemotherapy-Induced Nausea and Vomiting (CINV)
Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)
The purpose of this study is to examine the safety, tolerability, and efficacy of MK0517 to prevent Chemotherapy-Induced Nausea and Vomiting (CINV) associated with Cisplatin chemotherapy.
- Trial name
- EASE (NCT00619359)
- Testing
- Comparator: fosaprepitant dimeglumine, Comparator: Aprepitant, Dexamethasone
- Volunteers
- 2,322 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy Induced Nausea Vomiting
Combination of Netupitant and Palonosetron (Akynzeo®) in the Treatment of Refractory CINV
Prevention and control of Chemotherapy-Induced Nausea and Vomiting (CINV) are most important in treatment of cancer patients. CINV is one of the most distressing severe side effects of cancer treatment and can have a significant…
- Trial name
- CINV (NCT03008213)
- Testing
- Netupitant and Palonosetron
- Volunteers
- 4 people
- Sponsor
- Joseph Ma
Chemotherapy-induced Nausea and Vomiting
An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC
This prospective, multicenter, non-comparative, open-label trial design aims to evaluate the efficacy and safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in preventing nausea and vomiting induced by…
- Trial name
- NCT07482891
- Testing
- Fosrolapitant and Palonosetron Hydrochloride for Injection, Dexamethasone, Olanzapine
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai 6th People's Hospital
Nausea With Vomiting Chemotherapy-Induced, Depression, Reactive
Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer
A prospective longitudinal cohort study that will assess the effect of a Personalized Medicine (PM) clinic recommendations on pharmacogenetic variation and/or interacting drugs on plasma drug exposure, effectiveness or toxicity…
- Conditions
- Nausea With Vomiting Chemotherapy-Induced, Depression, Reactive, Cancer Pain
- Trial name
- NCT05830279
- Testing
- Pharmacogenetic testing, Drug-Drug interaction analysis
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Squamous Cell Carcinoma of Head and Neck, Chemotherapy Induced Nausea and Vomiting
A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting
The goal of this clinical trial is to investigate the effect of a nurse-led standardized intervention on chemotherapy induced nausea and vomiting (CINV) in patients with head and neck squamous cell carcinoma.
- Trial name
- NCT05792228
- Testing
- nurse-led standardized intervention
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Chemotherapy-Induced Nausea and Vomiting
A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)
This study will assess the bioequivalence of single oral doses of aprepitant (MK0869) to a single intravenous infusion of fosaprepitant (MK0517) and also determine the effect of food on the bioavailability of oral aprepitant.
- Trial name
- NCT00945321
- Testing
- aprepitant 165 mg, Comparator: aprepitant 185 mg, Comparator: fosaprepitant 150 mg
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors
To evaluate the efficacy and safety of HR20013 for injection for prevention of chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy.
- Trial name
- NCT05509634
- Testing
- HR20013 for injection；dexamethasone, fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
- Where
- China
- Volunteers
- 754 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Chemotherapy Induced Nausea and Vomiting
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 2 to 5 years.
- Trial name
- NCT01596426
- Testing
- Sancuso, IV granisetron
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd